$3.12
0.0%
Downside
Day's Volatility :13.57%
Upside
13.57%
43.91%
Downside
52 Weeks Volatility :66.67%
Upside
40.57%
Period | Cyclerion Therapeutics Inc | Index (Russel 2000) |
---|---|---|
3 Months | 12.29% | 0.0% |
6 Months | 12.29% | 0.0% |
1 Year | 10.4% | 0.0% |
3 Years | -95.35% | -20.2% |
Market Capitalization | 8.2M |
Book Value | $3.97 |
Earnings Per Share (EPS) | -4.55 |
Wall Street Target Price | 4.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -43.77% |
Return On Equity TTM | -158.12% |
Revenue TTM | 1.3M |
Revenue Per Share TTM | 0.59 |
Quarterly Revenue Growth YOY | 14.099999999999998% |
Gross Profit TTM | -29.7M |
EBITDA | -9.6M |
Diluted Eps TTM | -4.55 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
What analysts predicted
Upside of 28.21%
Sell
Neutral
Buy
Cyclerion Therapeutics Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Cyclerion Therapeutics Inc | 32.68% | 12.29% | 10.4% | -95.35% | -98.32% |
![]() Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
![]() Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
![]() Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
![]() Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Cyclerion Therapeutics Inc | NA | NA | NA | 0.0 | -1.58 | -0.44 | NA | 3.97 |
![]() Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
![]() Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
![]() Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
![]() Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Cyclerion Therapeutics Inc | Buy | $8.2M | -98.32% | NA | 0.0% |
![]() Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
![]() Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Cyclerion Therapeutics Inc
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 51.2%
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 281.9%
Slate Path Capital LP
MFN Partners Management, LP
TYNDALL CAPITAL PARTNERS L P
Tyndall Management, LLC
FMR Inc
Artal Group S A
cyclerion therapeutics, inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of various treatments for serious and orphan diseases. its product candidates include olinciguat, an orally administered vascular soluble guanylate cyclase (sgc) stimulator that is in phase ii studies for the treatment of sickle cell disease (scd); praliciguat, an orally administered systemic sgc stimulator that is in phase ii trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction; and iw-6463, an orally administered central nervous system (cns)-penetrant sgc stimulator, which is in phase i trials for neurodegenerative diseases. the company is also discovering liver-targeted sgc and lung-targeted sgc stimulators. cyclerion therapeutics, inc. was incorporated in 2018 and is headquartered in cambridge, massachusetts.
Organization | Cyclerion Therapeutics Inc |
Employees | 1 |
CEO | Dr. Regina Graul Ph.D. |
Industry | Pharmaceuticals: Major |
A Spac I Acquisition Corp
$3.12
-5.17%
Keyarch Acquisition Corp
$3.12
-5.17%
Connexa Sports Technologies Inc
$3.12
-5.17%
Us Value Etf
$3.12
-5.17%
First Wave Biopharma Inc
$3.12
-5.17%
Global X Msci Next Emerging
$3.12
-5.17%
Fat Projects Acquisition Corp
$3.12
-5.17%
Capital Link Global Fintech
$3.12
-5.17%
Applied Uv Inc
$3.12
-5.17%